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Abstract
Background—One of the long term complications of diabetes is the non-enzymatic addition of
glucose to proteins in blood, such as human serum albumin (HSA), which leads to the formation of
an Amadori product and advanced glycation end products (AGEs). This study uses 16O/18O-labeling
and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
to provide quantitative data on the extent of modification that occurs in the presence of glucose at
various regions in the structure of minimally glycated HSA.
Methods—Normal HSA, with no significant levels of glycation, was digested by various proteolytic
enzymes in the presence of water, while a similar sample containing in vitro glycated HSA was
digested in 18O-enriched water. These samples were then mixed and the 16O/18O ratios were
measured for peptides in each digest. The values obtained for the 16O/18O ratios of the detected
peptides for the mixed sample were used to determine the degree of modification that occurred in
various regions of glycated HSA.
Results—Peptides containing arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were
found to have 16O/18O ratios greater than a cut off value of 2.0 (i.e., a cut off value based on results
noted when using only normal HSA as a reference). A qualitative comparison of the 16O- and 18O-
labeled digests indicated that lysines 525 and 439 also had significant degrees of modification. The
modifications that occurred at these sites were variations of fructosyl-lysine and AGEs which
included 1-alkyl-2-formyl-3,4-glycoyl-pyrole, and pyrraline.
Conclusions—Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high
levels of modification and are also present near the major drug binding sites on HSA. This result is
clinically relevant because it suggests the glycation of HSA may alter its ability to bind various drugs
and small solutes in blood.
Keywords
Non-enzymatic glycation; human serum albumin; diabetes; matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry; 16O/18O-labeling; quantitative proteomics
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Introduction
Glycation is a process that involves the non-enzymatic addition of sugar molecules to the amino
groups of a protein, as occurs during diabetes [1]. The sites most susceptible to the initial stages
of glycation are normally found on lysine residues, but this process can also occur at the N-
terminus [1,2]. This initial phase involves the formation of a Schiff base, where a covalent
bond forms between a carbonyl group on the sugar and an amine group on the protein. However,
this Schiff base is an unstable intermediate that can go back to the initial reactants or rearrange
to create a more stable Amadori product. The Amadori product may then degrade and rearrange
through further reactions involving oxidation, dehydration, and cross-linking to form a mixture
of amino acid-linked substances called “advanced glycation end products” (AGEs). AGEs are
typically found on lysine and arginine residues, as well as the N-terminus [3,4]. AGEs that are
formed during diabetes are believed to contribute to the chronic micro and macro vascular
complications encountered in diabetes. Thus, there is a growing need for work that
characterizes and quantifies modified residues on glycated proteins [5].
Human serum albumin (HSA) was examined in this current study because it is the most
abundant protein in the serum and is known to undergo glycation [6–8]. This protein binds to
many drugs and analytes in the body [7] and it has been suggested that glycation may lead to
changes in the binding of some solutes with this protein [9]. There are a number of previous
studies that have sought to characterize AGEs and to identify glycation sites on various proteins
[10], including HSA [10–14]. Mass spectrometry is one tool that has been used to examine
modifications that occur as a result of glycation on proteins [15,16] and peptides [16,17].
However, few quantitative studies have been reported using this approach for examining the
modifications that occur in glycated HSA or in measuring early and late stage glycation
products in this protein [18].
In this study, isotopic labeling and matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) will be employed as tools for quantitative studies
comparing HSA and minimally glycated HSA that have been digested by serine proteases in
the presence of 16O- or 18O-enriched water (see general approach in Figure 1) [19–25]. The
resulting digests will be mixed in a fixed ratio, and the 16O/18O ratios of peptides found in this
mixed digest will be determined by using mass spectrometry, where all 16O/18O ratio
calculations are based on the peak areas present within an isotopic cluster [21,26]. If a
modification takes place in a given region of HSA due to glycation, an increase in the mass of
peptides from this region should occur; the result is that less of the non-modified peptide would
be seen in the glycated sample, causing the measured 16O/18O ratio to increase above levels
expected when no modification is present. In addition, the size of the 16O/18O ratio should
make it possible to compare the relative extent of glycation-related modifications that occur
in different regions of HSA.
These experiments will be conducted by using these tools from quantitative proteomics to
examine minimally glycated HSA that has been prepared in vitro. This previous research will
be expanded upon in this current study by using 16O/18O-labeling and MALDI-TOF MS to
rank the degree of modification that is occurring at such sites in HSA. Minimally glycated HSA
is of interest in this research because it is thought to mimic the extent of glycation seen in pre-
diabetes or early stages of this disease [27,28]. The results should provide a better
understanding of which regions on HSA are affected most by moderate levels of glycation and
provide clues as to how these modifications alter some of the properties of HSA (e.g., the ability
of this protein to bind drugs and small solutes).
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2. Theory
The theory behind the determination of 16O/18O ratios when using 16O- and 18O-labeling has
been described previously [19,29]. Two different methods for calculating 16O/18O ratios were
used in this report. The first method employed mass spectra for a 18O and 16O mixed digest
along with the expected relative intensities for unmodified peptides, as predicted by using
MSIsotope [30]. The 16O/18O ratio for a peptide in this case was determined by using the
following equation [29].
(1)
In this equation, the terms I0 through I5 represent the relative intensities for the M+0 to M+5
peaks in an isotope cluster, where M0 through M5 represent the expected relative intensities
for a digest in which no isotopic label is present. The terms in the first parentheses on the left
side of the denominator represent the 18O contribution for a peptide with one 18O label. The
terms in the second parentheses represent the 18O contribution for a peptide with two 18O
labels. This approach for determining 16O/18O ratios will be referred to as “Method 1”
throughout this paper.
The second method employed an internal standard by using the mass spectra obtained by
digesting HSA in 16O-enriched water instead of using a theoretical digest. As described in the
literature [19,23], a slightly modified form of this method can be used to simplify the
determination of a 16O/18O ratio. When a 16O digest and 18O digest are mixed in a 1:1 ratio,
an isotope peak in the mixed digest may be described as the sum of the contribution from
the 16O-labeled digest and the contribution from the 18O-labeled digest, as summarized in the
following equation.
(2)
In this equation, I′n represents the contribution from the 16O-labeled digest to the 16O-
and 18O-labeled mixed digest (In). Similarly, I″n represents the contribution from the 18O-
labeled digest to In.
When the relative intensities for the 16O- and 18O-labeled peptides are measured, these values
can be used to estimate the contribution from both the respective digests to the intensity of any
isotope peak in the mixed digest. The first step in this process is to rewrite eqn 2 in terms of
the individual 16O and 18O contributions (see eqn 3) and then to rearrange this equation into
the form given by eqn 4.
(3)
(4)
Barnaby et al. Page 3
Clin Chim Acta. Author manuscript; available in PMC 2011 August 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The terms a0 through a5 in these equations represent the relative intensities of the peaks in an
isotope cluster for a given peptide in the 16O-labeled digest, and the terms b0 through b5
represents the relative intensities for the same peaks in the 18O-labeled digest. The intercept
and slope of eqn 4 can be used to determine the 16O-label contribution to the M+0 peak (i.e.,
I′0) and the contribution of the 18O-label to the M+4 peak (i,e., I″4). Once I′0 and I″4 have been
obtained, these values can be used to estimate the 16O or 18O contribution to any peak in the
mixed spectra. An example is shown below, where the 18O contribution to the M+0 peak is
being determined.
(5)
A correction must be made for incomplete 18O incorporation during digestion because a
mixture of peptides with different degrees of 18O substitution will lead to overlapping isotope
peaks. The contribution of these overlapping peptides can be corrected by factoring in the
relative abundances from the 16O digest for peptides that contain one 18O atom (eqn 6) or
two 18O atoms (eqn 7).
(6)
(7)
In eqn 6, a correction is made for the M+2 isotope in the unlabeled peptide. Eqn 7 includes
two corrections, where the first correction is for the M+2 isotope in a peptide with one 18O
label and the second correction is for the M+4 isotope in a peptide with no 18O label.
The 16O/18O ratio can then be calculated by using these corrected variables as shown in the
following expression.
(8)
The concept behind eqn 8 is similar to eqn 1 but now uses the 16O digest as an internal standard
[23], with the relative abundances of these peaks (as well as those obtained from the 18O digest)
being used to estimate the 16O or 18O contribution to any given peak in the mixed spectra. The
advantage of using this method is that it allows corrections to be made for variations in the
actual extent of 18O incorporation and the type of instrumentation being employed. The
disadvantage of this method is that peptides have to be detected in all three digests for
the 18O/16O ratio to be determined. The use of this approach to determine 16O/18O ratios will
be referred to as “Method 2” in the remainder of this paper.
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3. Materials and Methods
3.1. Materials
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): Des-Arg-
bradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I (97%; acetate salt), HSA (99%,
essentially fatty acid and globulin free), glycated HSA (95%; lot number 115K6108, containing
1.8 mol hexose/mol HSA), sequencing grade trypsin, sequencing grade Glu-C, sequencing
grade Lys-C, guanidine HCl (99%), D/l dithiothreitol (99%), iodoacetamide (99%), formic
acid (96%), 2,5-dihydroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic acid (99%), 18O-
enriched water (97%), 16O-enriched water (99.99%), tris-HCl (99%) and ammonium
bicarbonate (99%). All of the chemicals that were used were reagent grade or better. The water
used for these experiments (other than that utilized for 18O-labeling) was obtained from a
Nanopure water system (Barnstead, Dubuque, IA)
3.2. Apparatus
The following items were purchased from Thermo Fisher Scientific (Rockford, IL): Slide-A-
Lyzer dialysis cassettes (7000 Da MW cutoff, 0.1 – 0.5 ml capacity) and a 0.5 – 10 μL digital
pipette. Micro-C18 ZipTip pipette tips with 5.0 μg of bed material were obtained from Millipore
(Billerica, MA). The overhead transparencies used for sample/matrix mixing prior to MALDI-
TOF MS were purchased from C-Line Products (Des Plaines, IL). Mass spectra were acquired
on a Voyager 6148 MALDI-TOF-MS system (Applied Biosystems, CA). The instrument
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100 ns;
accelerating voltage, 20 kV; guide wire voltage, 0.008% of accelerating voltage; grid voltage,
76% of accelerating voltage. The MSIsotope software was obtained from the UCSF Protein
Prospector webpage [30].
3.3. Sample Pretreatment, Digestions & Peptide Fractionation
The minimally glycated HSA obtained from Sigma-Aldrich was prepared under proprietary
conditions by incubating a fixed concentration of D-glucose with HSA at 37 °C for periods of
time that were no longer than a week. The HSA samples were pretreated as described previously
in work with immobilized HSA supports [19], but with the following modifications being made
for this study. A 5 mg/ml HSA solution prepared in denaturing buffer was used as described
in the previous study, however, the solution volume was now reduced from 1 ml to 300 μl to
reduce the amount of HSA that was used. The ratio of HSA to dithiothreitol and iodoacetamide
was kept the same as in Ref. [19] while the solution volumes were adjusted accordingly to
compensate for the change in the volume of the HSA solution. Digestion was carried out with
normal HSA being placed into 16O-labeled water and glycated HSA being digested in 18O-
labeled water. Zip-tip fractionation was performed as described previously by using aqueous
mixtures of 5, 10, 20, 30 and 50% acetonitrile for elution in a series of step gradients [19].
3.4. Mass Spectrometry & Data Acquisition
The details regarding the preparation of mass calibrants and matrix solutions are described
elsewhere [19]. The mass spectrometer was externally calibrated using a mixture containing
des-Arg-bradykinin (25 pmol/μl), glu-fibrinopeptide (32.5 pmol/μl), and angiotensin I (32.5
pmol/μl). A 4 μlL portion of this solution was mixed with 96 μl of α-cyano-4-hydroxycinnamic
acid and 2,5-dihydroxybenzoic acid mixed matrix solution (i.e., giving a final concentration
of 0.1–5 pmol/μl for the final calibration mixture), and the resulting mixture was spotted
adjacent to each sample well on a MALDI plate. A mass spectrum was obtained for the
calibration mixture using Voyager Control Panel software (Applied Biosystems, Foster City,
CA) and the file was exported to the Data Explorer software (Applied Biosystems). Using Data
Explorer, the monoisotopic M+0 peaks for des-Arg-bradykinin, glu-fibrinopeptide, and
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angiotensin I were calibrated to masses of 904.4681 Da, 1570.6774 Da, and 1296.6853 Da,
respectively. The calibration constants obtained were then saved and imported to the Voyager
software. The mass spectrum for the sample was then obtained. The calibration process was
repeated for every sample spot on the MALDI plate. The mass accuracy obtained when this
method was used was typically <50 ppm.
3.5. Peak Selection Criteria and Data Sorting
The masses of the peptides detected in the HSA or glycated HSA digests were compared to
the peaks predicted from a theoretical digest by using PEPTIDEMASS software [31,32]. When
generating the theoretical digest, the following considerations were made: the maximum
amount of missed cleavages was 2; all cysteine residues were assumed to be treated with
iodoacetamide; variable oxidation of methionine residues was allowed; and only monoisotopic
masses were selected. All peptides that could be matched within 50 ppm of the theoretical
digest were selected for further analysis [26]. For all digests, only peptides having a signal-to-
noise ratio greater than five were used for further quantitative studies. In the 18O digests, the
M+4 peak was used to determine the signal-to-noise ratio for the resultant peptides, while the
M+0 peak was used to determine the signal-to-noise ratio for the 16O digests. Information
about the pKa and the fractional accessible surface area (FAS) was used to predict the reactivity
of a given amino acid residue in forming glycation products; the methods used for calculating
these pKa and FAS values have been described previously in the literature [11,33,34].
4. Results and Discussion
4.1. Sequence Coverage
Prior to looking at the relative extent of glycation at various regions on HSA, the sequence
coverage for this protein was examined under the analysis conditions used in this study. When
using only qualitative data and looking for m/z values that could be linked to specific peptides,
the coverage obtained for the trypsin, Lys-C and Glu-C digests of HSA were found to be 83.6%,
61.0% and 54.0% respectively. The total coverage obtained when all three digests were
considered was 92.3%, which is close to a previously reported value of 97.4% under similar
pretreatment and analysis conditions for samples of soluble or immobilized HSA that were not
glycated [19].
When Method 1 was used to obtain 16O/18O ratios, the sequence coverage in these quantitative
studies was lowered to 51.5%, 53.9%, and 51.5% for the trypsin, Lys-C, and Glu-C digests
respectively, which gave a total sequence coverage for HSA of 83.6% (see Supplemental
Information). Similarly, when Method 2 was employed, the usable sequence coverage was
33.5%, 21.9%, and 42.1% for the trypsin, Lys-C, and Glu-C digests, respectively, which gave
an overall sequence coverage of 66.3% for HSA. This reduction in usable sequence coverage
in going from the qualitative to quantitative experiments was expected because several of the
peptides that were detected in the qualitative studies did not have a high enough intensity to
be used in the quantitative studies. This same type of reduction in sequence coverage has been
observed in previous studies using quantitative proteomics for immobilized versus soluble
HSA, where a total usable sequence coverage of 76.9% was obtained when quantitative data
was considered [19].
When using both Methods 1 and 2 for the quantitative studies, 16O/18O ratios could be
determined for peptides that encompassed 42 lysine and 21 arginine residues in HSA. By using
a qualitative comparison between the 16O- and 18O-labeled samples, K525 (found in residues
525–534 in the tryptic digest obtained in this study), was also found to have significant levels
of modification. The remaining 16 lysine and 3 arginine residues that were not included in
these peptides are located within residues 58–61, 160–163, 191–206, 295–317, 355–359, 520–
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524, 535–543 and 558–585. None of these residues, with the exception of K199 (a known site
of major glycation), is thought to undergo any significant amounts of modification during the
glycation of HSA [11,18,19,35]. Ongoing studies are currently being conducted to modify the
approach used in this work to include K199; however, it is also already known that this residue
is a prominent glycation site on HSA and is located at or near Sudlow site 1 [36].
4.2. Measurements of 16O/18O Ratios for Peptide Digests from Glycated HSA
Peptides containing a 16O/18O ratio higher than a cutoff value of 2.00 were selected and treated
as potential modification sites in the digests of glycated HSA. This cutoff value was determined
using a cumulative sums plot (Figure 2), where it was determined that 6% of the detected
peptide peaks had a 16O/18O ratio greater 2.00. This cutoff value is similar to an upper reference
value for 16O/18O ratios of 2.0–3.0 (depending on the type of digest being used) that has been
previously reported for this digestion and labeling approach with normal HSA [19].
The 16O/18O ratio range of 2.0–3.0 was previously obtained by comparing two control samples
of the same preparation of normal HSA [19]. When both Methods 1 and 2 were used for
quantitative analysis, the 16O/18O ratios for 83 peptides were determined. Of these peptides,
eight peptides containing four lysine residues and five arginine residues were identified as
major sites of modification because their 16O/18O ratios were above the selected cutoff ratio
of 2.0. Two peptides that encompass residues 525–534 and 415–439 on HSA were found to
have significant levels of modification; however, the extent of modification was too large to
be quantified by this current approach.
There were 2 cases where the 16O/18O ratio was calculated for peptides with identical residues
where one peptide had a cysteine that had been modified by iodoacetamide to form
carbamidomethyl-cysteine (CAM-cysteine) and the other peptide remained unmodified. These
two peptides were detected in the Glu-C digest and corresponded to residues 466–479 and
residues 101–119. In this situation, a pair of 16O/18O ratios was calculated for each residue,
where one ratio corresponds to the CAM-modified peptide and the other to the unmodified
peptide. In both cases, the unmodified peptides had a much higher 16O/18O ratio (1.27–1.86)
than their CAM-modified counterparts (0.31–0.37). This anomaly may indicate that CAM-
incorporation was not consistent between the glycated HSA and the reference HSA samples.
Because of this, the 16O/18O ratio for the CAM-modified peptide in this case was assumed to
be the 16O/18O ratio that most closely represented glycation.
The 16O/18O ratios obtained for the tryptic digest using Method 1 and 2 are given in Tables 1
and 2, respectively. In the tryptic digest, five peptides were found to have 16O/18O ratios >2.00.
A total of 3 peptides were also noted in the Lys-C digest that had 16O/18O ratios greater than
2.00, but the Glu-C digest gave no peptides with 16O/18O ratio above this cutoff value (see
Supplemental Information).
Table 3 shows the ranking of the peptides that were found in the quantitative studies to have
major degrees of modification, as listed according to the order of their 16O/18O ratios. These
peptides contained amino acids R114, R81, R218, K413, K432, K159, K212 and/or R209, and
K323. Of these residues R218, K159 and R209 were found to be modified to produce the AGEs
1-alkyl-2-formyl-3,4-glycoyl-pyrole (AFGP), pyrraline (Pyr) and AFGP, respectively.
Similarly, residues 212, 413 and 432 were modified to form fructosyl-lysine (FL), FL-2H2O
and FL-2H2O, respectively, all of which are early stage glycation products. The procedure used
for identifying these modifications was based on a Perl-script algorithm, as described in Ref.
[11]. In some cases, a manual comparison was also performed using a simplified search list
(i.e., only one modification allowed per peptide) as based on previously-identified
modifications [11].
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There were 2 instances where the m/z values for a given peptide were clearly detected in
the 16O digest, but the same m/z values were not found in the 18O digests or mixed labeled
digest (see Table 3). The absence of these characteristic peptides in the 18O digests is indicative
of significant glycation, because the concentration of the unmodified forms of these peptides
were too low to be detected at the selected signal-to-noise threshold of 5 (i.e., only peaks with
intensities below this threshold were noted in the 18O and mixed oxygen labeled digests). Low
intensity m/z values corresponding to residues 525–534 (1128.69 Da) in the tryptic digest and
residues 415–439 (2629.42 Da) in the Lys-C digest were found only in the 16O-labeled digest.
Interestingly, these residues also correspond to lysines 439 and 525, which are amongst the
most commonly cited glycated lysine residues in HSA [18]. Supporting evidence of this was
found previously in that K525 was shown to be modified to form Nε–carboxyethyl-lysine
(CEL) and K439 was shown to be modified to form FL [11]. In addition to these peptides, a
section from residues 226–233 is also believed to have significant levels of modification. A
set of m/z values corresponding to this peptide (880.44 Da), were clearly identified in the 16O-
and 18O-labeled digests; however, the corresponding m/z value in the mixed digest seemed to
shift to 881.29 Da. This shift would result in a value that falls outside the assigned mass
accuracy. Nevertheless, a 16O/18O ratio was calculated for this peptide, giving an 16O/18O ratio
of 4.32, indicating that this peptide could potentially contain high levels of glycation. Previous
studies have indicated that K233, which is found within residues 226–233 of HSA, may be
glycated [18].
The 16O/18O ratios for other modifications that occur on glycated HSA which did not exceed
the 2.00 cutoff value were also considered, based on possible modifications that have been
noted in the literature in qualitative studies with HSA [11]. If multiple 16O/18O ratios could be
linked to a given lysine or arginine residue, the resulting 16O/18O ratios that are modified to
form CAM-cysteine and peptides that have a minimum combination of lysine and/or arginine
residues were used to assign the most likely glycation sites. This was done to provide the most
realistic representation of the 16O/18O ratio for a given amino acid, without the influence of
CAM modified cysteine or assigning 16O/18O ratios that result from multiple minor
modifications to a single amino acid. When CAM modification and lysine/arginine
heterogeneity are factored in, the range of 16O/18O ratios for lysines 12 and 51 (or the N-
terminus) is 1.18–1.32 and 1.28–1.78 respectively. These results indicate that K51 (or the N-
terminus) contains the most early glycation products, followed by K12. These amino acid
residues have previously been linked to the formation of early stage glycation products (i.e.,
FL-related modifications). Similarly, the range of 16O/18O ratios for AGE-linked peptides
[11] containing K159, K286, K378, R472 and R222 is 1.80–2.40, 0.26–0.28, 0.45–1.29, 0.31–
0.50 and 1.62–1.86, respectively. When these residues are ranked in order of
decreasing 16O/18O ratios, K159 appears to have the largest extent of AGE-modification
followed by R222, K378, R472 and K286. Lysines 159, 378, and 286 were linked to Pyr, CEL,
and CML respectively. Similarly, arginines 222 and 472 were linked to G-H1 and ArgP
respectively.
The peptide with the highest detected 16O/18O ratio of 3.77 was detected in the trypsin digest
and had a mass of 940.45 Da. This corresponds to residues 107–114 on HSA, which indicates
that R114 is modified to form AGEs. The particular type of modification could not be identified
by m/z shifts in this study or in our previous study [11], however, early glycation does not occur
on arginine residues so it likely being modified to form AGEs. Similarly, a peptide (933.52
Da) with a high 16O/18O ratio of 3.68 was detected in the trypsin digest. This corresponds to
residues 74–81 on HSA, indicating that R81 may be involved in AGE formation. Several
peptides were identified in this analysis that had high 16O/18O ratios with corresponding
glycation related m/z shifts as identified previously [11]. For example, a high 16O/18O ratio
peptide corresponding to residues 213–218 (673.38 Da) on HSA has previously been shown
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to be modified by AFGP. Similar cases where high 16O/18O ratios and glycation related
modifications can be linked are shown in Table 3.
4.3. Peptides with High 16O/18O Ratios Representing Early or Advanced Glycation Products
Some of the peptides containing 16O/18O ratios above the cutoff ratio had multiple sites for
possible modification. As a result it was difficult to link an increased 16O/18O ratio to a
particular amino acid in the respective peptide. For peptides with several possible modification
sites, the detected mass shifts were used to help assign the sites that were being modified. For
instance, peptide 403–413 (1352.77 Da) detected in the Lys-C digest had a 16O/18O ratio of
3.29 and contained both K413 and R410. A separate peptide was found from the same region
(residues 403–413) that had a mass shift of 126 Da. This mass shift corresponds to modification
by FL-2H2O, suggesting that K413 is being modified during glycation to form this type of
adduct. Similarly, lysines 432 and 212 were clearly identified as likely modification sites
because the m/z shift data that was obtained previously [11] show that these amino acids were
being modified by early glycation products.
There were some glycation-related mass shifts that were identified in this study (Table 4) and
linked to peptides with intermediate 16O/18O ratios. The resulting mass shifts were similar to
the mass shifts that were obtained previously [11]. For instance, amino acids K106, K136,
K240, K174, K466,, and R336 are suspected to be modified to produce CML, FL-2H2O,
FL-1H2O, FL and CEL, CEL, and AFGP respectively. Of these residues, lysines 136, 174, and
240 were previously shown to be modified by FL-1H2O, CEL, and FL-1H2O, respectively
[11]. All of the other modifications that were linked to intermediate 16O/18O ratios are new to
this current study. Of these residues, K432 and K413 were linked to 16O/18O ratios that were
above the cutoff ratio of 2.00. The number of m/z shifts that were linked to
intermediate 16O/18O ratios in this study and in Ref. [11] illustrates the heterogeneous nature
of glycation-related modifications and the need for improved characterization techniques.
4.4. Correlation of Modifications with Local pKa or FAS Values
Additional sources of information can be used to determine which lysine or arginine residues
on HSA might be prone to modifications by glycation. This information includes the estimated
pKa values for the individual amino acid side chains, the FAS (i.e., fractional accessible surface
area) for each of these residues, and the location (surface or buried) of the amino acid residue.
Lysine or arginine residues on HSA having low pKa values would be expected to be more
susceptible to glycation reactions because a larger portion of these residues would exist in a
non-protonated state, favoring nucleophilic addition/substitution [11]. Amino acid side chains
with high FAS values and residues that occur on the surface of a protein such as HSA could
be more reactive because they have greater access to reactants compared to sites buried within
the protein’s structure. Another factor to consider is that HSA is a flexible protein [7] in which
changes in confirmation may facilitate or hinder glycation reactions. As a result, the
aforementioned variables are not static, and residues with low FAS values, high pKa values or
that are normally buried within the protein may become more reactive as glycation-induced
conformational changes occur.
Of the various residues with high 16O/18O ratios that were noted in this study (Table 3), residues
R218, R410, and R428 are all buried within the structure of HSA, while the majority of the
remaining residues are located on the surface of HSA. In addition, lysines 233, 439, and 525,
which are believed to have undergone significant glycation based on a qualitative comparison
of the digest, are all found on the surface of HSA. This result makes sense because the majority
of modification that occurs on HSA is expected to occur with residues that are easily accessible
to sugars in the surrounding medium. When looking at the modifications which were identified
by mass shifts (Table 4), six of these modifications occur on residues that are found on the
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surface of the protein and five occur on residues that are more buried in the structure of HSA.
The location of AGEs or glycation products in the buried locations could be explained by
changes in the structure of HSA when glycation occurs. Changes in the confirmation of HSA
that was glycated both in vitro and in vivo were observed in a prior study [35]. Further evidence
of this was indicated previously, when K199 was identified as a prominent glycation site. Even
though the location of this residue is buried within the structure of HSA, it has consistently
been identified as a glycation site that occurs on HSA [11,37]. Additional information, such
as the calculated pKa and FAS values for these residues, were next used to provide further
insight into these modification processes.
The range of calculated pKa values for the lysine and arginine residues on HSA are 6.23–11.11
and 7.56–16.02, respectively, where the lysine residues have an average pKa value of 10.08
and the arginine residues have an average pKa of 12.34 (Note: details on how these calculated
results were obtained are provided in the literature [19]). The peptides listed in Table 3 appear
to follow a trend in which the most frequently occurring modifications took place on residues
that either have pKa values below the average or have high FAS values. For instance, R114,
R81, and R209 have FAS values of 0.80, 0.76, and 0.61, respectively, which are on the high
end of the range of FAS values for arginine. These residues are also suspected modification
sites based on their 16O/18O ratio values. R218 has the highest FAS value of all arginines on
HSA, a pKa value which is lower than average, and the highest calculated 16O/18O ratio in this
study. All of these features provide strong evidence that this residue is a likely site for
modification due to glycation-related reactions. Similarly, lysines 413, 432, and 212 were
assigned as glycation sites because of the corresponding low pKa values, lysine specific
modifications were identified on these peptides, and peptides corresponding to these residues
all had high 16O/18O ratios. Similar assignments were made for m/z shifts that were identified
in this study that corresponded to early or late stage glycation adduct formation (Table 4). Of
the glycation sites that were identified through a qualitative comparison of the digests, lysine
439 had a high FAS value of 0.94, which partially explains the reactivity of this residue. The
reactivity of K233 and K525, however, cannot be explained based on the pKa or FAS values
alone because these values are more typical of those seen for other lysines on HSA. It is
therefore likely that some other process such as a conformational change upon glycation [35]
or localized acid-base catalysis [18] may increase the amount of modification that occurs on
these residues.
4.5. Location of Modified Sites versus Major Drug Binding Sites on HSA
It has been suggested that the extent of glycation of HSA may affect how tightly HSA binds
drugs and small solutes in the body [7,38–40]. The two major drug binding sites on HSA,
commonly referred to as the Sudlow sites 1 and 2, contain several amino acids which facilitate
the binding of these compounds to HSA [7,38–40]. When the results from Tables 1 and 2 are
compared to the location of these binding sites [7], many of the potential glycation sites are at
or near the same regions on HSA that facilitate drug and solute binding. For instance, K212,
K233, R209, and R218 (noted in Table 3 to be potentially important sites for modifications
due to glycation) occur in the same vicinity as the key residues W214 and F211 that are found
in Sudlow site 1. Similarly, K413, K432, K439, are located in the same region of HSA as R410
and Y411, which are important residues taking part in drug interactions at Sudlow site 2. Of
the major glycation adducts that were noted in this study (Table 4), K432 and K240 occur in
the same region of HSA as L430 (Sudlow site 2) and L234/l238 (Sudlow site 1), respectively.
These results suggest that the glycation of HSA, even at the minimal levels examined in this
report, may have a potential effect on the binding of drugs and other small solutes at these sites
on HSA.
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5. Conclusions
Figure 3 shows an image of HSA (as created using the Visual Molecular Dynamics software
[41]) that summarizes the results found in this study. This figure includes the major glycation/
modification sites identified in this study and lists their 16O/18O ratios. When ranked in order
of decreasing 16O/18O ratios, R114, R81, R218, K413, K432, K159, K212, and K323 were
found to give significant changes in their 16O/18O ratios due to glycation or a reaction that
produced AGEs. In addition to these peptides, lysines 439, 525, and 233 are also believed to
contain significant amounts of modification based on this work. These possible modification
sites were obtained by combining information on the observed mass shifts for the affected
peptides in the digests, the 16O/18O ratios for these peptides, the location of the peptides in
HSA, and the corresponding pKa and FAS values that were calculated for the given residues.
The approach discussed in this report is novel because it allows for the simultaneous
quantification of glycation-related products that occur on lysine and arginine residues in HSA.
It was clearly established in this work that significant glycation and AGE-modifications occur
at or near the two major drug binding sites of HSA, which explains the changes in binding
affinity that have been noted for some endogenous solutes with glycated HSA (e.g., bilirubin
and fatty acids) [35,40,42]. These modifications also explain, in part, changes in the binding
of various drugs with HSA or in serum during diabetes [43–45]. The clinical implication of
these findings is that protein glycation and related modifications might affect the protein
binding and, thus, the drug activity that occurs in persons with diabetes compared to non-
diabetic patients. The results of this work also complement and build on previous work in the
analysis of glycation-related modifications [5,12,13] by providing a relative ranking of the
amount of glycation that is found in various portions of minimally glycated HSA.
Future work will explore the extension of this approach to HSA containing various levels of
glycation and to glycated HSA that is found in vivo. A comparison of the results of such studies
with this current report and past studies should make it possible to get a more complete picture
of how glycation patterns may vary for HSA in clinical samples or under various reaction
conditions. Modification of the techniques used in this study to allow a higher sequence
coverage of HSA (e.g., including lysine 199) [46] are also being considered and experiments
are planned that will examine the rates at which various portions of HSA are modified as a
result of glycation. Studies with various pharmaceutical agents are also in progress to see how
drug-protein interactions change for various preparations of glycated HSA. The expected result
is information that can be used by physicians in personalized medicine to help design and
modify treatment drug treatments for patients with diabetes.
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CAM carbamidomethyl
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Figure 1.
General procedure for obtaining quantitative estimates of glycation based on 18O-labeling
MALDI-TOF MS. The non-modified peptides from HSA are represented by a–c, while a*–c*
represent modified peptides from the same regions of glycated HSA.
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Figure 2.
Bar chart showing the cumulative sum of all the detected peaks as a function of 16O/18O ratio
range for Methods 1 ( ) and 2 ( ). The number of 16O/18O ratios that were greater than or
equal to the indicated16O/18O ratio range were used for this plot. The relative amount of the
number of 16O/18O ratios is also given as a percentage.
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Figure 3.
Structure of HSA, showing the peptides with significant glycation-related modifications that
were found in minimally glycated HSA and the corresponding arginine or lysine that was
modified in this region. The values of the measured indicated 16O/18O ratios are also provided,
where applicable. This image was generated from a PDB file with accession number 1AO6
[46].
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